StockData
Fate Therapeutics Inc logo

Fate Therapeutics Inc (FATE) stock

FATENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3021% below fair value
$1.05+0.03 (+2.94%)

Close on Nov 18, 2026Market cap $125.81MP/E –Yield –

Fate Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Fate Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$105.62M. For fiscal 2025 it was -$112.04M. The highest annual figure on record is -$12.15M in fiscal 2011.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$112.04M–
FY2024Dec 31, 2024-$123.60M–
FY2023Dec 31, 2023-$138.42M–
FY2022Dec 31, 2022-$283.77M–
FY2021Dec 31, 2021-$213.57M–
FY2020Dec 31, 2020-$44.16M–
FY2019Dec 31, 2019-$90.57M–
FY2018Dec 31, 2018-$40.95M–
FY2017Dec 31, 2017-$38.54M–
FY2016Dec 31, 2016-$30.28M–
FY2015Dec 31, 2015-$19.90M–
FY2014Dec 31, 2014-$23.30M–
FY2013Dec 31, 2013-$15.62M–
FY2012Dec 31, 2012-$13.98M–
FY2011Dec 31, 2011-$12.15M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$23.48M–
Q1 FY2026Mar 31, 2026-$31.06M–
Q4 FY2025Dec 31, 2025-$24.51M–
Q3 FY2025Sep 30, 2025-$26.58M–
Q2 FY2025Jun 30, 2025-$25.95M–
Q1 FY2025Mar 31, 2025-$35.01M–
Q4 FY2024Dec 31, 2024-$27.90M–
Q3 FY2024Sep 30, 2024-$29.91M–
Q2 FY2024Jun 30, 2024-$32.36M–
Q1 FY2024Mar 31, 2024-$33.44M–
Q4 FY2023Dec 31, 2023-$36.82M–
Q3 FY2023Sep 30, 2023-$38.84M–
Q2 FY2023Jun 30, 2023-$30.69M–
Q1 FY2023Mar 31, 2023-$32.07M–
Q4 FY2022Dec 31, 2022-$82.07M–
Q3 FY2022Sep 30, 2022-$63.72M–
Q2 FY2022Jun 30, 2022-$63.29M–
Q1 FY2022Mar 31, 2022-$74.70M–
Q4 FY2021Dec 31, 2021-$88.66M–
Q3 FY2021Sep 30, 2021-$48.11M–
Q2 FY2021Jun 30, 2021-$45.73M-219.7%
Q1 FY2021Mar 31, 2021-$31.08M–
Q4 FY2020Dec 31, 2020-$22.94M–
Q3 FY2020Sep 30, 2020-$31.69M–
Q2 FY2020Jun 30, 2020$38.21M–
Q1 FY2020Mar 31, 2020-$27.74M–
Q4 FY2019Dec 31, 2019-$28.13M–
Q3 FY2019Sep 30, 2019-$21.10M–
Q2 FY2019Jun 30, 2019-$22.10M–
Q1 FY2019Mar 31, 2019-$19.24M–
Q4 FY2018Dec 31, 2018-$12.14M–
Q3 FY2018Sep 30, 2018-$4.28M–
Q2 FY2018Jun 30, 2018-$11.80M–
Q1 FY2018Mar 31, 2018-$12.74M–
Q4 FY2017Dec 31, 2017-$11.52M–
Q3 FY2017Sep 30, 2017-$10.13M–
Q2 FY2017Jun 30, 2017-$9.28M–
Q1 FY2017Mar 31, 2017-$7.61M–
Q4 FY2016Dec 31, 2016-$7.59M–
Q3 FY2016Sep 30, 2016-$7.55M–

More Fate Therapeutics figures

See a number that looks wrong?